

Stock Options (Right to Buy)	\$ 125.05	11/12/2021		M			27,159	(11)	08/09/2024	Common Stock	27,159	\$ 0	799	D
Stock Options (Right to Buy)	\$ 125.05	11/16/2021		M			799	(11)	08/09/2024	Common Stock	799	\$ 0	0	D
Stock Options (Right to Buy)	\$ 177.32							(11)	08/08/2025	Common Stock	13,550		13,550	D
Stock Options (Right to Buy)	\$ 177.32							(12)	08/08/2025	Common Stock	18,066		18,066	D
Restricted Stock Units	(10)							(13)	(13)	Common Stock	3,151		3,151	D
Stock Options (Right to Buy)	\$ 190.41							(13)	08/07/2026	Common Stock	15,948		15,948	D
Stock Options (Right to Buy)	\$ 190.41							(14)	08/07/2026	Common Stock	21,265		21,265	D
Restricted Stock Units	(10)							(15)	(15)	Common Stock	2,575		2,575	D
Stock Options (Right to Buy)	\$ 267.87							(15)	08/05/2027	Common Stock	11,488		11,488	D
Stock Options (Right to Buy)	\$ 267.87							(16)	08/05/2027	Common Stock	15,318		15,318	D
Stock Options (Right to Buy)	\$ 267.87							(17)	08/05/2027	Common Stock	24,975		24,975	D
Stock Options (Right to Buy)	\$ 267.87							(18)	08/05/2027	Common Stock	24,975.00		24,975.00	D
Restricted Stock Units	(10)							(19)	(19)	Common Stock	1,556		1,556	D
Stock Options (Right to Buy)	\$ 481.82							(19)	08/06/2028	Common Stock	6,080		6,080	D
Stock Options (Right to Buy)	\$ 481.82							(20)	08/06/2028	Common Stock	8,107		8,107	D

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Eansor Norman David 8100 SOUTHPARK WAY, A-8 LITTLETON, CO 80120			President-Protein Sciences	

Signatures

/s/ Andrew Nick as Attorney-in-Fact for N. David Eansor pursuant to Power of Attorney previously filed.

**Signature of Reporting Person

11/16/2021

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 - (1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$503.78 to \$504.535, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
 - (2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$502.62 to \$503.33, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
 - (3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$503.77 to \$504.745, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
 - (4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$504.97 to \$505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
 - (5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$502.11 to \$503.10, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
 - (6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$503.11 to \$504.107, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
 - (7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$504.13 to \$505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
 - (8) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$505.13 to \$506.07, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
 - (9) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$506.20 to \$506.275, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
 - (10) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
 - (11) Fully exercisable.
 - (12) Options to purchase 4,517 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 4,516 shares vest on each of 8/8/2021 and 8/8/2022.
 - (13) Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
 - (14) Options to purchase 5,317 shares vest on 8/7/2020 and options to purchase 5,316 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.
 - (15) Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
 - (16) Options to purchase 3,830 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 3,829 shares vest on each of 8/5/2023 and 8/5/2024.
 - (17) Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
 - (18) Options to purchase 8,325 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
 - (19) Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
 - (20) Options to purchase 2,027 shares vest on each of 8/6/2022, 8/6/2023 and 8/6/2024 and options to purchase 2,026 shares vest on 8/6/2025.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.